Methyltestosterone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06710 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | short stature due to growth hormone qualitative anomaly | KG + DL |
| 2 | pituitary hormone defiency from vascular origin | KG + DL |
| 3 | non-acquired combined pituitary hormone deficiencies without extra-pituitary malformations | KG + DL |
| 4 | hypogonadotropic hypogonadism-frontoparietal alopecia syndrome | KG + DL |
| 5 | X-linked intellectual disability with isolated growth hormone deficiency | KG + DL |
| 6 | hypogonadotropic hypogonadism with or without anosmia | KG + DL |
| 7 | short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia | KG + DL |
| 8 | Leydig cell hypoplasia due to LH resistance | KG + DL |
| 9 | 46,XY disorder of sex development due to impaired androgen production | KG + DL |
| 10 | combined pituitary hormone deficiencies, genetic form | KG + DL |
| 11 | Kaplowitz-Bodurtha syndrome | KG + DL |
| 12 | hypogonadotropic hypogonadism | KG + DL |
| 13 | late-onset isolated ACTH deficiency | KG + DL |
| 14 | Kallmann syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.